MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
KIHT can now conduct clinical research for drugs and medical devices, strengthening evidence generation and healthcare innovation
Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
Collaboration aims to accelerate medicinal chemistry decision-making, reduce synthesis burden and strengthen data-secure AI adoption in drug discovery
Recognition places pharmaceutical excipients leader among the top 5% of companies globally, highlighting progress in emissions reduction, responsible sourcing, and sustainable supply chain practices
Premium CBD+THC-infused gummies target stress relief, relaxation, and sleep recovery
World MS Day 2026 conclave brings together MPs, neurologists, disability rights advocates and insurance stakeholders to push for reforms in healthcare access, disability recognition and social protection
India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time
We are contributing to the Indian pharmaceutical and laboratory sectors through advanced analytical instrumentation, automated liquid handling, and molecular biology solutions. Our technologies empower research and Quality Control (QC) by ensuring regulatory compliance and streamlined workflows…
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
